Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change
- PMID: 20147682
- PMCID: PMC2837461
- DOI: 10.2105/AJPH.2009.162982
Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change
Abstract
Older adults are vastly underrepresented in clinical trials in spite of shouldering a disproportionate burden of disease and consumption of prescription drugs and therapies, restricting treatments' generalizability, efficacy, and safety. Eliminating Disparities in Clinical Trials, a national initiative comprising a stakeholder network of researchers, community advocates, policymakers, and federal representatives, undertook a critical analysis of older adults' structural barriers to clinical trial participation. We present practice and policy change recommendations emerging from this process and their rationale, which spanned multiple themes: (1) decision making with cognitively impaired patients; (2) pharmacokinetic differences and physiological age; (3) health literacy, communication, and aging; (4) geriatric training; (5) federal monitoring and accountability; (6) clinical trial costs; and (7) cumulative effects of aging and ethnicity.
References
-
- Smedley BD, Syme SL. Promoting Health: Intervention Strategies From Social and Behavioral Research. Washington, DC: National Academies Press; 2000 - PubMed
-
- Institutes of Medicine Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academies Press; 2000 - PubMed
-
- Haynes A, Smedley BD. The Unequal Burden of Cancer: An Assessment of NIH Research and Programs for Ethnic Minorities and the Medically Underserved. Committee on Cancer Research Among Minorities and the Medically Underserved. Health Sciences Policy Program Health Sciences Section. Washington, DC: National Academies Press; 1999 - PubMed
-
- Murthy VH, Krumholz H, Gross GP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720–2726 - PubMed
-
- Townsley CA, Pond GR, Oza AM, et al. Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. Clin Cancer Res. 2006;12(7 pt 1):2141–2149 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical